AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.
First and Only System in the United States Approved to Treat Patients
with Persistent and Long-Standing Persistent Atrial Fibrillation
WEST CHESTER, Ohio, Dec 16, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems and systems for the exclusion of the
left atrial appendage, today announced that the U.S. Food and Drug
Administration (FDA) has approved AtriCure's Synergy Ablation...
First and Only System in the United States Approved to Treat Patients
with Persistent and Long-Standing Persistent Atrial Fibrillation
WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 16, 2011--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems and systems for the exclusion of the
left atrial appendage, today announced that the U.S. Food and Drug
Administration (FDA) has approved AtriCure’s Syn...
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 17, 2011--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems and systems for the exclusion of the
left atrial appendage, today announced that it has closed enrollment in
its DEEP AF feasibility trial. DEEP AF was designed to evaluate the
safety and efficacy of combining AtriCure’s minimally invasive products
with catheter technologies to treat patients w...
WEST CHESTER, Ohio, Nov 10, 2011 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems and systems for the exclusion of the
left atrial appendage, today announced that it will participate in the
following upcoming investor conferences:
The Lazard Capital Markets 8th Annual Healthcare Conference
at the Pierre Hotel in New York. Management is scheduled to present on
...
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
